Administrative supplement for Fusion Lumos mass spectrometer

Fusion Lumos 质谱仪的行政补充

• 批准号: 9708201
• 负责人: Scott A. Gerber
• 金额: $ 17.44万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-15 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9708201
• 关键词: Address; Administrative Supplement; Auxins; Binding; Biological Process; Biology; Cell Line; Cells; Centrioles; Chemicals; Cytokinesis; DNA Damage; Diabetes Mellitus; Disease; Emerging Technologies; Enzymes; Family; Family member; G1 Phase; Gene Deletion; Gene Expression; Goals; Half-Life; Hour; Human; In Vitro; Individual; Knowledge; Label; Malignant Neoplasms; Mass Spectrum Analysis; Methods; Mitosis; Mitotic; Molecular Target; Mutation; Nerve Degeneration; Oncogenes; PLK1 gene; Pathway interactions; Pharmacotherapy; Phosphorylation; Phosphorylation Site; Phosphotransferases; Polo-Box Domain; Post-Translational Protein Processing; Process; Proteins; Proteomics; RNA Interference; Recovery; Regulation; Research; Research Personnel; Signal Pathway; Signal Transduction; Site; Substrate Interaction; Testing; Time; Tumor Suppressor Proteins; Yeasts; analog; base; chemical genetics; clinical effect; clinically relevant; experimental study; genetic approach; genome sequencing; human disease; inhibitor/antagonist; interest; mass spectrometer; member; mutant; nanomolar; overexpression; phosphoproteomics; protein degradation; response; small molecule; small molecule inhibitor; therapy resistant

PROJECT SUMMARY Protein phosphorylation is an essential post-translational modification (PTM) that controls most biological processes. More than three-quarters of all proteins are phosphorylated at one or more sites in human cells. Systematic genome sequencing, gene expression and RNAi studies have implicated deregulation of kinase function in many human diseases, including cancer, diabetes, and neurodegeneration. However, such approaches do not reveal specific signaling pathways and molecular targets. Thus, there is an unmet need for the systematic interrogation of human kinase-substrate relationships. The long-term goal of our research is to decipher kinase signaling in basic biology and disease. To accomplish this, we have developed and applied quantitative phosphoproteomics strategies to connect specific kinases to their substrates, including for Polo- like kinase 1 (Plk1). Plk1 is the founding member of the Plk family and is conserved from yeast to humans. Plk1 is an essential regulator of recovery from DNA damage and mitotic entry, mitotic progression and cytokinesis, and is frequently overexpressed in cancer. While Plk1 is a bona fide oncogene, Plk2 and Plk3 act as tumor suppressors, protect cells against DNA damage, and are required for other G1 and S-phase processes, although the mechanisms that underlie these functions are largely unknown. Traditional strategies to selectively study kinase function such as gene deletion, depletion, or overexpression alter kinase abundance on a time scale of hours to days which often precludes assignment of direct kinase substrates. Elegant chemical genetics approaches that introduce mutations into the conserved catalytic kinase domain to render them ATP analog-sensitive have been implemented to overcome the general lack of selective inhibitors and the temporal control problem. However, these mutations often reduce kinase activity and stability, limiting the universal implementation of this approach. Thus, new strategies are needed for connecting kinases and their substrates. To address this gap in capability, we propose to establish a general quantitative chemical proteomics strategy to enable the identification of specific kinase substrates. Inducible protein degradation is an emerging technology for directly manipulating protein abundance. We hypothesize that the combination of inducible, rapid protein degradation (< 10 min half-life) and mass spectrometry based proteomics is a viable strategy for the identification of specific kinase substrates and elucidation of phosphorylation signaling networks of closely related enzymes. In this proposal, we provide a blueprint for comprehensive studies of kinase–substrate relationships on a kinome-wide level. This is pivotal for mapping cellular signaling pathways, identifying kinase pathway reprogramming upon disruption by mutations or drug treatment and resistance, and determining off-target effects of clinically relevant inhibitors. More than half of the human kinome is un- or under-characterized; experiments outlined here represent a roadmap for filling this gap in knowledge.

项目总结 蛋白质磷酸化是一种重要的翻译后修饰(PTM)，它控制着大多数生物 流程。超过四分之三的蛋白质在人类细胞中的一个或多个位置被磷酸化。 系统的基因组测序、基因表达和RNAi研究已经牵涉到了对激酶的放松调控 在许多人类疾病中发挥作用，包括癌症、糖尿病和神经退行性变。然而，这样的 方法不揭示特定的信号通路和分子靶点。因此，有一种未得到满足的需求 对人的激酶-底物关系的系统研究。我们研究的长期目标是 破译基础生物学和疾病中的激酶信号。为了实现这一目标，我们开发并应用了 定量磷酸蛋白质组学策略将特定的激酶连接到它们的底物，包括Polo- 如蛋白激酶1(Plk1)。PLK1是PLK家族的创始成员，从酵母到人类都是保守的。 PLK1是DNA损伤恢复、有丝分裂进入、有丝分裂进程和 胞质分裂，在癌症中经常过度表达。虽然plk1是真正的癌基因，但plk2和plk3起作用 作为肿瘤抑制因子，保护细胞免受dna损伤，是其他G1期和S期所必需的 虽然这些功能背后的机制在很大程度上是未知的。传统战略 有选择地研究激酶功能，如基因缺失、缺失或过表达改变激酶丰度 从几个小时到几天的时间尺度上，这往往排除了直接激酶底物的分配。雅致 将突变引入保守的催化激酶结构域的化学遗传学方法 它们对三磷酸腺苷类似物敏感，以克服普遍缺乏选择性抑制剂和 时间控制问题。然而，这些突变往往降低了激酶的活性和稳定性，限制了 这一方法的普遍实施。因此，需要新的策略来连接激酶和它们的 底物。为了解决这一能力差距，我们建议建立一种通用的定量化学物质 蛋白质组学策略，以实现特定的激酶底物的鉴定。可诱导蛋白质降解是 一种直接控制蛋白质丰度的新兴技术。我们假设这两个因素的结合 可诱导的、快速的蛋白质降解(10分钟半衰期)和基于质谱学的蛋白质组学是可行的 鉴定特定的激酶底物和阐明磷酸化信号转导的策略 密切相关的酶网络。在这项建议中，我们提供了一个全面研究的蓝图 在整个基因组水平上的激酶-底物关系。这对于绘制细胞信号通路至关重要， 确定突变或药物治疗和耐药中断时的激酶途径重新编程，以及 确定临床相关抑制剂的非靶点效应。超过一半的人类亲属没有或 描述不足；这里概述的实验代表了填补这一知识空白的路线图。